New Mathematical Implementation of Generalized Pharmacodynamic Models: Method and Clinical Evaluation

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of pharmacokinetics and biopharmaceutics

• Publication date

  1997-06-01

• Fields of study

  Mathematics, Medicine

• Identifiers
  DOI 10.1023/A:1025723725312PMID 9474531
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Simultaneous analysis of verapamil and norverapamil enantiomers in human plasma by high-performance liquid chromatography.

  1995cited by this paper
• Verapamil stereoisomers during racemic verapamil administration: Effects of aging and comparisons to administration of individual stereoisomers

  1994cited by this paper
• Time Course of Drug Effect

  1994cited by this paper
• Pharmacodynamic system analysis of the biophase level predictor and the transduction function.

  1992cited by this paper
• A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling.

  1991influential reference
• Trends in the Pharmacokinetics of Drug-Receptor Interactions

  1991cited by this paper
• Semiparametric analysis of non-steady-state pharmacodynamic data

  1991cited by this paper
• Epistemology in Pharmacokinetics

  1991cited by this paper
• The heart rate-PR interval relationship: a model for evaluating drug actions on SA and AV nodal function.

  1990cited by this paper
• Optimized Inhalation Aerosols. I. The Effects of Spherical Baffle Size and Position upon the Output of Several Pressurized Nonaqueous Suspension Formulations

  1989cited by this paper
• Semiparametric approach to pharmacokinetic-pharmacodynamic data.

  1989cited by this paper
• Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions.

  1989cited by this paper
• A system approach to pharmacodynamics. I: Theoretical framework.

  1988cited by this paper
• Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models

  1986cited by this paper
• Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.

  1984cited by this paper
• Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration.

  1984cited by this paper
• Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model

  1984cited by this paper
• The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.

  1983cited by this paper
• Intraindividual variability in theophylline pharmacokinetics: Statistical verification in 39 of 60 healthy young adults

  1982cited by this paper
• The Pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses

  1982cited by this paper
• A method for estimating within-individual variability in clearance and in volume of distribution from standard bioavailability studies

  1982cited by this paper
• Comparison of intravenous and oral verapamil dosing

  1982cited by this paper
• Simultaneous pharmacokinetic and pharmacodynamic modeling

  1981cited by this paper
• Verapamil disposition kinetics in chronic atrial fibrillation

  1981cited by this paper
• Monotone Piecewise Cubic Interpolation

  1980influential reference
• Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

  1980cited by this paper
• Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment

  1980cited by this paper
• Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine

  1979cited by this paper
• A pharmacodynamic model for pancuronium.

  1978cited by this paper
• Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT

  1977influential reference
• A new look at the statistical model identification

  1974cited by this paper
• A Simplex Method for Function Minimization

  1965cited by this paper
• Pharmacokinetics of

  year unknowncited by this paper

• Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.

  2000cites this paper
• Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.

  2000cites this paper
• Advantages of toxicokinetics in new drug development.

  1998cites this paper
• Bioavailability Assessment from Pharmacologic Data: Method and Clinical Evaluation

  1997cites this paper